The HIV drug space has narrowed in recent years, now down largely to two major players – Gilead Sciences Inc., which continues to hold the top spot, and ViiV Healthcare, the GlaxoSmithKline PLC/Pfizer Inc. joint venture founded in 2009.
ViiV has begun to gain ground on Gilead, powered by the strength of recent launches, though Gilead has maintained its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?